Skip to Main Content

Paper Details

Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
Haematologica
18
2022
AML, AML cells, FLT3, FLT3 mutations, FLT3-ITD, FLT3-ITD AML, LZTR1, MAPK, MEK, MTOR, MTOR complex1, MTORC1, NF1, TSC1, TSC2, acute myeloid leukemia, crenolanib, patient, patients, quizartinib, sorafenib
Antineoplastic Agents, Cell Line, Tumor, Clustered Regularly Interspaced Short Palindromic Repeats, Humans, Leukemia, Myeloid, Acute, MAP Kinase Signaling System, Mutation, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, Sorafenib, TOR Serine-Threonine Kinases, Transcription Factors, fms-Like Tyrosine Kinase 3
Author NameAffiliation
Alisa DamnernsawadKnight Cancer Institute, Oregon Health and Science University, Mahidol University
Daniel BottomlyKnight Cancer Institute, Oregon Health and Science University
Stephen E KurtzKnight Cancer Institute, Oregon Health and Science University
Christopher A EideKnight Cancer Institute, Oregon Health and Science University
Shannon K McWeeneyKnight Cancer Institute, Oregon Health and Science University
Jeffrey W TynerKnight Cancer Institute, Oregon Health and Science University
Tamilla NechiporukKnight Cancer Institute, Oregon Health and Science University
  • 1 - 7

Datasets

Release 1.2